Skip to main content
Publications
Li X, Hodgson D, Flaig J, Kieffer A, Herring WL , Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P, REspiratory Syncytial virus Consortium in EUrope (RESCEU) Investigators. Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study . Value Health. 2023 Apr;26(4):508-18. doi: 10.1016/j.jval.2022.11.014
Lin S, Kahangire DA, Nagar S , Ahn M, Affi R, Agulnik J, Shih J, Hockmair MJ, Tufman A, Debieuvre D, Chow J, Jimenez M , Davis KL , Sandelin M, Veluswamy R. Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study . Poster presented at the European Lung Cancer Congress 2023; March 31, 2023. Copenhagen, Demark.
Simmons DJ, Blank SV, Nagar S , Nham T , Long GH, Davis KL , Wetherill G, Munley J, McLaurin K. Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: retrospective US cohort study . Poster presented at the SGO 2023 Annual Meeting on Women's Cancer; March 27, 2023. Tampa, FL.
Ahn M, Kang JH, Kim S, Kahangarie D, Nagar SP , Davis KL , Jimenez M , Seo M, Jung M, Sandelin M, Cho BC. Treatment (tx) patterns and outcomes in resectable early-stage NSCLC in South Korea: subgroup analysis of a global real-world (rw) study . Poster presented at the ESMO Asian Congress 2023; December 2, 2023. Singapore, China. [abstract] Ann Oncol. 2023; 34(Suppl 4):S1646-53.
Furqan M, Karanth S , Goyal RK , Shih Y, Cai B, Rombi J , Davis KL , Caro N, Saliba TR. Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14) . Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023; 4((Suppl 16):e21112.
Abdulkareem NM, Bhat R, Powell RT, Chikermane S, Yande S , Trinh L, Abdelnasser HY, Tabassum M, Ruiz A, Sobieski M, Nguyen ND, Johnson M, Kaipparettu BA, Johnson CA, Bond RA, Stephan C, Triveni MV. Screening of GPCR drugs for repurposing in breast cancer . Front Pharmacol. 2022 Dec 6;13:1049640. doi: 10.3389/fphar.2022.1049640
Shih JY, Lin SH, Nagar SP , Davis KL , Jimenez MI , Kahangire DA, Servidio L, Ho L, Veluswamy R. Treatment patterns in resectable early-stage NSCLC in Taiwan: subgroup analysis of a global real-world study . Poster presented at the 2022 ESMO Asia Congress; December 2, 2022. Singapore, Republic of Singapor.
Mellott C, Jaworski R, Carrico J, Clinkscales M, Talbird S , Dobrowolska I, Golicki D, Tsoumani E, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland . Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S117. doi: 10.1016/j.jval.2022.09.568
Talbird S , Graham J , Anderson S , Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Health and economic impact of a novel 3-antigen vaccine for the prevention of hepatitis B in adults in Germany: a cost-effectiveness analysis . Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S135. doi: 10.1016/j.jval.2022.09.649
Talbird S , Graham J , Anderson S , Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Cost-effectiveness and epidemiological impact of a novel 3-antigen vaccine for the prevention of Hepatitis B in adults in the United Kingdom . Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. doi: 10.1016/j.jval.2022.09.782
Li X, Hodgson D, Flaig J, Kieffer A, Herring W , Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P. Cost-effectiveness of Respiratory Syncytial Virus (RSV) prevention interventions in children: a model comparison study . Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec; 25(12S):S178. doi: 10.1016/j.jval.2022.09.861